The Food and Drug Administration (FDA) has approved a label change for Isentress (raltegravir; Merck) to include updated information about concomitant raltegravir and aluminium and/or magnesium-containing antacids.
The new label update states that coadministration or staggered administration of aluminum and/or magnesium hydroxide-containing antacids with Isentress is not recommended. New data showed that the coadministration of aluminum and magnesium antacid within six hours of Isentress significantly decreased raltegravir plasma levels. The previous label for Isentress had recommended against coadministration or to stagger by two hours with aluminum and magnesium antacids.
Isentress is a HIV-1 integrase strand transfer inhibitor indicated for the treatment of HIV-1 infection in patients ≥4 weeks of age, in combination with other antiretrovirals.
For more information call (877) 888-4231 or visit Isentress.com.